I think it's just a typo. The share register as of the 6th show he held just over 10% the RNS states he now holds 16%. He has bought 70m shares.
Hi JD yes at the moment the deadline for full and H1 are by 30th September but most companies are using the extension to take into account the full impact of Covid. The Bod however have already reported that they have had minimal impact by the pandemic and the unaudited accounts are showing 35% revenue increase for the full year to £169 m and £1.18 m profit after taxes.
So they may release full year accounts prior to the deadline, but we’ll see. It does look extremely positive at the moment and a lot more in the pipeline for this year especially with them now looking at the UK market. I am looking forward to some great news to come from this company.
Hi OB, from what I have read H1 reports must be produced within 3 months of H1 end and at present there are no extensions to this time frame. But this will be under review and can obviously change.
I’ve read a few negative posts on this board saying that this company is not worth investing in because its mark cap is £11 m and it only made a net profit of £0.4 m in 6 months with a meagre 37% increase in revenue.
Yet people are willing to invest in mining and oil exploration companies with much higher Mcaps yet produce no revenue at all. Go figure.
We have a company here who’s revenue has grown every year and is showing a very reasonable profit and has just signed a deal with Moneygram.
This deal allows the transfer of money to over 200 countries instead of their existing 10.
Now surely these are exactly the fundamentals of a company in which it is worth investing in.
Re-cap - Revenue, profit, growth and new deal = more growth.
Sorry forgot to mention that this is just the US market for this one product. So many more markets for this and much more in the pipeline, all very positive.
Sounds fantastic, looks like Eton Pharma are expecting Alkindi Sprinkle to be one of their biggest sellers and revenue producers at over $100 m yearly. No wonder the possible large buys are taking place.
Fantastic interview. Huge Gold potential but also Copper and Nickel. Game changer!
Everyone should listen to this.
HSDL showing at 15 pence.
NSCI is not just about the value of PDSB we have huge value in our other holdings. The news has just strengthened investors sentiment and confidence in NSCI as a whole.
Hopefully the American market opens up on a positive and helps to push this up.
These RNSs are great news and I feel we won't have to wait long for for the next ones to drop, stating the unnamed Global Pharma and licensing/royalty agreements.
RNS-significantly oversubscribed.
Does this mean then that there is the potential that some large UK institutions still want in on these shares.
Up for sale, then come collaborations with twoGlobal Pharma companies. Removed from sale then raised £5 million and the placing was significantly oversubscribed and brings new UK institutions into the Company's shareholder base.
Something big on its way!!!
Thanks MB, I am actual finding your posts quite interesting and informative now and I'm enjoying reading them now unlike before when I thought they were just the rantings of a possessed mad man!
I agree that the company has taken the right steps on re-focussing its goals and finding that its future is in collaborations and partnerships. I think that the current Global pandemic is probably opening up more doors to the smaller companies with great tech as the Major Global Pharma don't want to miss out on the potential that exits with huge Government funding and forward purchasing.
As for the Secura Bio legal issue we can only hope that this ends in a swift and amicable result which would benefit all involved, especially the sick children who could benefit from this.
We have to remember that MTPH hold 107 patents covering their core technologies so we have value from all those years of hard work and money spent, it is by law and if Global Pharmas want it and need it then they will have to pay for it in licensing or royalties or both.
Below link to the July corporate presentation for people who have not seen it.
http://www.midatechpharma.com/uploads/investor_files/20.07.06%20Corporate%20Overview.pdf
This is purely speculation on my behalf, but has any one else thought that there could be a potential Covid-19 play in action here.
Just seems quite coincidental that with all the Covid drug trials at the moment that this is when we have collaboration with two Global Pharma companies and we specialise in superior drug administration technologies.
This is the news release from Dr Reddy's:
Hyderabad, India, July 01, 2020 - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:
RDY, hereafter referred to as “Dr. Reddy’s”) announces partnering with FUJIFILM Corporation through
FUJIFILM Toyama Chemical Co. Ltd. (hereafter referred to as “FUJIFILM”) and Global Response Aid
(hereafter referred to as “GRA”) for the development, manufacture and sales of Avigan® Tablets (generic
name: favipiravir), a potential treatment of COVID-19.
Under the tripartite agreement signed on 30th June 2020, FUJIFILM grants Dr. Reddy’s the exclusive rights
of manufacturing and also grants both Dr. Reddy’s and GRA the rights to develop, sell and distribute
Avigan® in all countries other than Japan, China and Russia. Dr. Reddy’s would have exclusive rights for
development, selling and distribution of Avigan® in India. Further, FUJIFILM would receive an upfront
license fee and royalties on sales from Dr. Reddy’s and GRA.
FUJIFILM will provide Dr. Reddy’s and GRA with an array of data on Avigan®’s preclinical and clinical
studies that FUJIFILM has accumulated thus far. Dr. Reddy’s and GRA will use this data for clinical studies
targeting COVID-19 in regions where infection has been spreading. In addition, FUJIFILM will grant
Dr.Reddy’s right to use Avigan®’s patents of formulation and manufacturing method. Dr. Reddy’s will
herewith establish a setup for manufacturing drugs of the same quality as Avigan®, and utilize GRA’s
global sales network to supply the manufactured drugs swiftly and in a stable manner.
The FUJIFILM Group is currently conducting a clinical study on Avigan® targeting COVID-19 patients in
Japan and the US, and is working to increase the drug’s production by partnering with domestic and
overseas companies. Dr. Reddy’s and GRA shall introduce the product in the market post all applicable
approvals in the respective countries.
About Avigan® Tablets
Avigan® Tablet, developed by FUJIFILM Toyama Chemical, was approved for manufacture and sale in
Japan in 2014 as an influenza antiviral drug. The drug is to be considered for use only when there is an
outbreak of novel or re-emerging influenza virus infections in which other influenza antiviral drugs are
either not effective or insufficiently effective, and the Japanese government decides to use the drug as a
countermeasure against such influenza viruses.
Now my thoughts are what if they need Midasolve to allow tablet based drugs to be administered by injection or intravenously to be more effective against Covid.
Even Q-Sphera to allow for prolonged release of effective drug
Since MTPH announced its sale process to the open market in April it has entered into two collaborations with Global companies.
1. June 8, 2020 Midatech Pharma PLC, an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, today announces it has entered into a research collaboration with Dr Reddy's, one of the global pharmaceutical companies, committed to accelerating access to affordable and innovative medicines.
Midatech will deploy its in-house expertise and proprietary drug delivery platforms towards comprehensive improvement of bio-delivery and bio-distribution of medicines nominated by Dr Reddy's. Novel products arising from the collaboration are expected to benefit from precision clinical performance and advanced manufacturing technology and, critically, it is anticipated will advance the joint mission of both companies to make medicines that enable treatments, to address unmet patient needs and strive towards 'Good Health'.
Sam Barker, Director of Business Development of Midatech, said: "This partnership with Dr Reddy's is further recognition of the power of Midatech Pharma's unique drug delivery technology to improve and expand treatment options for patients. We are delighted to be able to combine our technology with innovative industry partners, such as Dr Reddy's, potentially enabling the unique qualities of this technology to reach beyond our own internal development pipeline for the benefit of all patients."
2. July 21, 2020 Midatech Pharma PLC, a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines announces it has entered into a research collaboration for the Q-Sphera platform with a European affiliate of a global pharmaceutical company.
Within the multi-project collaboration, Midatech will deploy its in-house expertise and proprietary drug delivery platforms towards assets nominated by the pharmaceutical company.
The feasibility studies may establish the application of the Q-Sphera platform to new modalities in drug delivery. Novel assets and products arising from the collaboration will be the property of the pharmaceutical company and in the event that the feasibility study is successful, the pharmaceutical company would be required to enter into a licence agreement to use the Q-Sphera platform.
Why would you remove the company from sale after only three months when the company has enough cash to last into 2Q2021, surely you you would keep the sales process going until then.
The only reason I can see for them doing this is that there is huge news to come from these collaborations and revenue streams.
Just seems odd that they would do it as soon as they were able to and not wait a while. Maybe a requirement of the new collaboration with Global Pharma.
Who knows, but strange timings. Just speculation though as no proof or facts as yet.
Statement from NASDAQ news release.
In company news, Midatech Pharma (MTP) fell nearly 11% after the UK-based drugmaker said it was scrapping the formal sale process it announced April 20 although it will continue to evaluate several early-stage proposals from unnamed third parties for selected assets as well as a separate reverse-merger transaction. The company Thursday said it has not received any new acquisition offers over the past three months, allowing it to terminate the offer period as defined under UK securities law.
Maybe they wanted to terminate the sales process earlier due to new collaborations but couldn't due to UK law requiring three months to pass. Just my opinion.
Buys showing as sells, makes it look like people are selling when they're not.
Yes I agree, the takeover was mentioned back in June in a presentation and did nothing to the SP.
This movement was all about the new collaboration with Global Pharma. News still to come!!
Buys showing as sells, 60 to buy at moment.